Loading…
ACH-PROGESTERONE is a brand name for Progesterone, supplied as a capsule. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: , 1.1 Pediatrics, 1.2 Geriatrics 03/2026
Verbatim from this product's HC label. Tap a section to expand.
4 Geriatrics 03/2026 TABLE OF CONTENTS Certain sections or subsection that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed. RECENT MAJOR LABEL CHANGES ...........................................................................................
2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
4 1 INDICATIONS ............................................................................................................... 1 Pediatrics .....................................................................................................................
2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ..................................................................................................
4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.............................................................. 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 1 Dosing Considerations ..........................................................................................................
2 Recommended Dose and Dosage Adjustment..................................................................... 4 Administration. .....................................................................................................................
5 Missed Dose…… .................................................................................................................... 6 5 OVERDOSAGE ..............................................................................................................
6
Some of the information presented in the Warnings and Precautions section is provided in light of the fact that progestin medication is often prescribed concomitantly with an estrogen medication. Information in this section pertaining to combined estrogen-progestin therapy may therefore not apply to progestin-only therapy.
Health Care Professional discretion is advised. 1 Dosing Considerations Pregnancy should be excluded before initiating HRT. 2 Recommended Dose and Dosage Adjustment Hormone Replacement Therapy: For initiation and continuation of hormone replacement therapy (estrogens and progesterone) in postmenopausal symptoms, the lowest effective dose for the shortest duration should be used (see also Section 7 WARNINGS AND PRECAUTIONS).
e. from day 8 to day 21 for a 28-day cycle, and from day 12 to day 25 for a 30-day cycle). 25 mg conjugated estrogens or higher) should be administered 300 mg daily for the last 12-14 days of estrogen treatment. Page 6 of 39ACH-PROGESTERONE Product Monograph Unclassified / Non classifié The dosage of ACH-PROGESTERONE should be proportional to the dosage of estrogen.
With adequate adjustment of the dosage of ACH-PROGESTERONE, patients should experience either regular withdrawal uterine bleeding or cessation of bleeding (amenorrhea). ACH-PROGESTERONE is not indicated for pediatric use. 4 Administration ACH-PROGESTERONE is formulated for oral administration and must be swallowed whole.
Capsules should not be chewed, crushed nor pierced. The 200 mg daily dosage of ACH-PROGESTERONE should be taken at bedtime. Patients receiving 300 mg of ACH-PROGESTERONE daily should take one capsule (100 mg) in the morning and two capsules (200 mg) at bedtime.
The morning dose should be taken 2 hours after breakfast. Concomitant food ingestion significantly increases the bioavailability of micronized progesterone. 5 DRUG-FOOD INTERACTIONS. 5 Missed Dose If a patient is treated with 200 mg daily (total dose at bedtime) and she forgets to take this dose, she should take a dose of one capsule (100 mg) the following morning and continue taking the rest of the capsules as prescribed.
4 Geriatrics 03/2026 TABLE OF CONTENTS Certain sections or subsection that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed. RECENT MAJOR LABEL CHANGES ...........................................................................................
2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
4 1 INDICATIONS ............................................................................................................... 1 Pediatrics .....................................................................................................................
2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ..................................................................................................
4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.............................................................. 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 1 Dosing Considerations ..........................................................................................................
2 Recommended Dose and Dosage Adjustment..................................................................... 4 Administration. .....................................................................................................................
5 Missed Dose…… .................................................................................................................... 6 5 OVERDOSAGE ..............................................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Progesterone in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
If a patient is treated with 300 mg daily, and she forgets to take a morning or evening dose, she should not take the missed dose. 5 OVERDOSAGE The toxicity of progesterone is very low. Symptoms that may occur are: nausea, vomiting, somnolence and dizziness.
Progestin (norethindrone acetate) overdosage has been characterized by depressed mood, tiredness, acne and hirsutism. For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669).
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING Table 1: Dosage Forms, Strengths, Composition Route of Administration Dosage Form / Strength Non-medicinal Ingredients Oral Capsule, 100 mg progesterone ammonium hydroxide, black iron oxide, gelatin, glycerin, isopropyl alcohol, soya lecithin, medium chain triglyceride, n-butyl alcohol, propylene glycol, purified talc, shellac glaze, sunflower oil and titanium dioxide Page 7 of 39ACH-PROGESTERONE Product Monograph Unclassified / Non classifié ACH-PROGESTERONE (micronized progesterone) 100 mg capsules to be taken orally; contain 100 mg micronized progesterone as the active ingredient.
ACH-PROGESTERONE 100 mg capsule is a round shape, opaque, white to off white colour, soft gelatin capsule free from surface defect, imprinted "MS" in black ink containing off white colour suspension. Packaging ACH-PROGESTERONE 100 mg progesterone capsules are available in unit dose blister packages, with 30 capsules per package and bottles of 100 capsules.
7 WARNINGS AND PRECAUTIONS See 3 SERIOUS WARNINGS AND PRECAUTIONS BOX. General ACH-PROGESTERONE is NOT a contraceptive and must only be used in accordance with the indications in Section 1 INDICATIONS. 5 mg of soya lecithin and may cause hypersensitivity reactions (urticarial and anaphylactic shock in hypersensitive patients).
As there is a possible relationship between allergy to soya and allergy to peanut, patients with peanut allergy should avoid using Progesterone Soft Capsules. Progesterone Soft Capsules contain highly refined oil, for which the incidence of hypersensitivity is very rare in adults.
Carcinogenesis and Mutagenesis Breast Cancer Available epidemiological data indicate that the use of combined estrogen plus progestin by postmenopausal women is associated with an increased risk of invasive breast cancer. 5 mg/day), among 10,000 women over a one-year period, there were: • 8 more cases of invasive breast cancer (38 on combined HRT versus 30 on placebo).
1] vs. 04) and were at a more advanced stage compared with those diagnosed in the placebo group. The percentage of women with abnormal mammograms (recommendations for short-interval follow-up, a suspicious abnormality, or highly suggestive of malignancy) was significantly higher in the estrogen plus progestin group versus the placebo group.
This difference appeared at year one and persisted in each year thereafter. 625 mg/day), there was no statistically significant difference in the rate of invasive breast cancer in […]
6 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................................... 6 7 WARNINGS AND PRECAUTIONS ................................................................................... 1 Special Populations ....................................................................................................
1 Pregnant Women ...................................................................................................... 2 Breast-feeding............................................................................................................
3 Pediatrics ................................................................................................................... 4 Geriatrics ...................................................................................................................
13 8 ADVERSE REACTIONS ................................................................................................. 1 Adverse Reaction Overview ........................................................................................
2 Clinical Trial Adverse Reactions .......................................................................................... 5 Post-Market Adverse Reactions ..................................................................................
16 9 DRUG INTERACTIONS ................................................................................................. 2 Drug Interactions Overview ...............................................................................................
4 Drug-Drug Interactions ....................................................................................................... 5 Drug-Food Interactions ......................................................................................................
6 Drug-Herb Interactions....................................................................................................... 7 Drug-Laboratory Test Interactions .....................................................................................
18 10 CLINICAL PHARMACOLOGY ........................................................................................ 1 Mechanism of Action .........................................................................................................
2 Pharmacodynamics ............................................................................................................ 3 Pharmacokinetics ...............................................................................................................
19 11 STORAGE, STABILITY AND DISPOSAL .......................................................................... 20 PART II: SCIENTIFIC INFORMATION ......................................................................................
21 13 PHARMACEUTICAL INFORMATION ............................................................................. 21 14 CLINICAL TRIALS.........................................................................................................
1 Clinical Trial by Indication................................................................................................... 2 Comparative Bioavailability Studies ..................................................................................
27 16 NON-CLINICAL TOXICOLOGY ...................................................................................... 28 17 SUPPORTING PRODUCT MONOGRAPHS ..................................................................... 30 PATIENT MEDICATION INFORMATION .................................................................................
31 Page 4 of 39ACH-PROGESTERONE Product Monograph Unclassified / Non classifié PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS ACH-PROGESTERONE […]